Pontoon - clinically, the trial does not have to prove efficacy to be a success. It has to prove lack of toxicity, safety for humans, dose for forward trials need to be established, confirmation or lack of will be proven for p21 activation. Proven efficacy will be bonus - but is not primary endpoint for this phI. It is secondary endpoint - meaning the trial can be considered success even if efficacy not proven.
My personal speculation is that efficacy will be seen. That is why I am in this stock. That is speculation - separate from the trial.
